NEW YORK (GenomeWeb) – Inozyme Pharma said today that it is instituting a no-cost genetic testing program in partnership with Wisconsin-based PreventionGenetics to improve the detection and understanding of two rare calcification disorders for which the drugmaker is developing treatments.
The program will offer free testing to eligible individuals with a suspect family history for mutations in the ENPP1 and ABCC6 genes, which are implicated in rare, severe calcification disorders, known as ENPP1 deficiency and ABCC6 deficiency, respectively.
The two companies are hoping that this may help individuals with these disorders be identified and diagnosed more quickly.
Inozyme CEO and co-founder Axel Bolte said in a statement that the effort will help to enhance the company's understanding of ENPP1 deficiency and ABCC6 deficiency, "with the ultimate goal of improving diagnosis and developing effective treatments."